Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 5:7:385.
doi: 10.3389/fmed.2020.00385. eCollection 2020.

Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors

Alessandra Pulvirenti  1 , Antonio Pea  2   3 , David K Chang  2   3 , Nigel B Jamieson  2   3
Affiliations
Review

Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors

Alessandra Pulvirenti et al. Front Med (Lausanne). .

Abstract

Well-differentiated pancreatic neuroendocrine tumors are increasingly diagnosed neoplasms. For localized disease, surgery is the first-line therapy and is curative in most cases. However, although recurrence is a rare event, it can still occur up to 10 years from surgery, worsening the prognosis. Many clinical and pathological factors have been associated with recurrence; however, it is currently unclear how to accurately discern patients at risk for relapse of disease from those that should be considered cured. In this review, we focus on clinical, pathological, and molecular factors associated with recurrence and discuss available prediction tools to assess the risk of recurrence following surgery.

Keywords: molecular markers; neuroendocrine tumors; pancreatic neuroendocrine tumors; pancreatic surgery; recurrence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PanNET pattern of recurrence following surgical resection (14, 17).
See this image and copyright information in PMC

References

    1. Klimstra DS, Kloppell G, La Rosa S RG. Classification of neuroendocrine neoplasms of the digestive system. In: Board WC. editor. WHO Classification of Tumours of the Digestive System Tumours. 5th ed. Lyon: International Agency for Research on Cancer; (2019). p. 16.
    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol. (2017) 26:2124–30. 10.1001/jamaoncol.2017.0589 - DOI - PMC - PubMed
    1. Pulvirenti A, Marchegiani G, Pea A, Allegrini V, Esposito A, Casetti L, et al. . Clinical Implications of the 2016. International study group on pancreatic surgery definition and grading of postoperative pancreatic fistula on 775 consecutive pancreatic resections. Ann Surg. (2018) 268:1069–75. 10.1097/SLA.0000000000002362 - DOI - PubMed
    1. Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, et al. . Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. (2016) 22:1011–7. 10.1158/1078-0432.CCR-15-0548 - DOI - PMC - PubMed
    1. Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, et al. . Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study. Ann Surg Oncol. (2016) 23:1721–8. 10.1245/s10434-015-5013-2 - DOI - PubMed

LinkOut - more resources